Frazier Life Sciences

Frazier Life Sciences 的所有者是 Frazier Healthcare Partners.

Frazier Healthcare Partners 拥有 4家子公司，其中包括 Comprehensive Pharmacy Services、Elevate Patient Financial Solutions 和 Frazier Life Sciences。

他们在：

• 基金40%
• 医疗设备20%
• 其他40%

涉及Frazier Healthcare Partners的并购和融资。

• Frazier Healthcare Partners 已收购 RevSpring (公布2024三月14号).

查看带有其 25 名主要高管的组织结构图

Frazier Life Sciences 搜索最多的简介

• Albert Cha, Co-Managing Partner
• Patrick Heron, Co-Managing Partner
• James Topper, Co-Managing Partner

高管在Frazier Life Sciences变化

• James Li已作为Venture Partner加入公司  (新闻发布的2024十二月13号).

高管在Frazier Healthcare Partners变化

• Lindsey Murphy已作为Director of Sales Operations加入公司  (新闻发布的2024六月14号).
• Sanji Fernando已作为Partner, Data and Artificial Intelligence加入公司  (新闻发布的2024六月14号).

创建提醒
跟踪 Frazier Life Sciences 的高管变动

Frazier Healthcare Partners 拥有 1,534 家竞争者，其中包括 BlackRock (美国(美洲))、Vanguard (美国(美洲)) 和 Blackstone Group (美国(美洲))。

Popular M&A news in 基金

• Cansortium 已收购 RIV Capital (公布2024十二月20号).
• RIV Capital and Cansortium have announced they will merge  (公布2024十月14号)..
• Janus Henderson Group 已收购 Victory Park Capital (公布2024十月7号).

基金 行业的其他推荐联系人

• Valor Equity Partners 企业 Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer
• Vanguard 企业 Salim Ramji - Chief Executive Officer and Director
• General Catalyst Partners 企业 Hemant Taneja - Chief Executive Officer and Managing Director

了解更多有关基金行业的信息 >

Frazier Life Sciences 的最新新闻稿

• Frazier Life Sciences Appoints Experienced Biotech Innovator and Global Business Leader, James Li, as Venture Partner
• Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550
• Gilead and Tubulis announce agreement on ADC · Tubulis News
• Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors
• Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement - Jade Biosciences
• Frazier Life Sciences Adds Industry Veteran and Serial Dealmaker, Adam Simpson, to Company Creation Team
• Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline - Scorpion Therapeutics
• Disc Medicine Announces Underwritten Offering of Common Stock | Disc Medicine Inc.
• Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer
• Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
• View more press releases Close

关于 Frazier Life Sciences 的社交媒体

• Frazier Life Sciences 在 维基百科、谷歌新闻 和 雅虎财经
• Frazier Life Sciences 在 LinkedIn、叽叽喳喳 和 YouTube

通过电子邮件联系联系该企业高管，包括 Steve Bailey

致电Frazier Life Sciences，电话：+1 206...

查看组织结构图

Register to receive your alert

报告错误